Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abayomi B Ogundele

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Clinical Ophthalmology (Auckland, N.Z.)|December 29, 2010
Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbitsAbayomi B Ogundele, Mark C Jasek
Clinical Ophthalmology (Auckland, N.Z.)|August 7, 2010
In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%Abayomi B Ogundele, David Earnest, Marsha A McLaughlin
Clinical Ophthalmology (Auckland, N.Z.)|February 27, 2010
Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbitsAbayomi B Ogundele, Guangming Li, Joel J Ellis
Diagnostic Microbiology and Infectious Disease|June 7, 2005
Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer centerPatrick F Smith, Brent M Booker, Abayomi B Ogundele, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|November 24, 2004
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administrationLawrence A Trissel, Christopher A Saenz, Abayomi B Ogundele, et al.
Clinical Ophthalmology (Auckland, N.Z.)|December 31, 2010
Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertensionDietmar Schnober, Günter Hofmann, Hubert Maier, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|October 3, 2003
Using medium-fill simulation to establish a benchmark microbiological contamination rate for low-risk-level compoundingLawrence A Trissel, Abayomi B Ogundele, Delshalonda S Ingram, et al.
Pharmacotherapy|March 1, 2006
Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteersDesiree L Tomilo, Patrick F Smith, Abayomi B Ogundele, et al.
Clinical Ophthalmology (Auckland, N.Z.)|May 2, 2019
A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteersPaul M Karpecki, Sidney L Weiss, William G Kramer, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Clinical Ophthalmology (Auckland, N.Z.)|December 29, 2010
Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbitsAbayomi B Ogundele, Mark C Jasek
Clinical Ophthalmology (Auckland, N.Z.)|August 7, 2010
In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%Abayomi B Ogundele, David Earnest, Marsha A McLaughlin
Clinical Ophthalmology (Auckland, N.Z.)|February 27, 2010
Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbitsAbayomi B Ogundele, Guangming Li, Joel J Ellis
Diagnostic Microbiology and Infectious Disease|June 7, 2005
Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer centerPatrick F Smith, Brent M Booker, Abayomi B Ogundele, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|November 24, 2004
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administrationLawrence A Trissel, Christopher A Saenz, Abayomi B Ogundele, et al.
Clinical Ophthalmology (Auckland, N.Z.)|December 31, 2010
Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertensionDietmar Schnober, Günter Hofmann, Hubert Maier, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|October 3, 2003
Using medium-fill simulation to establish a benchmark microbiological contamination rate for low-risk-level compoundingLawrence A Trissel, Abayomi B Ogundele, Delshalonda S Ingram, et al.
Pharmacotherapy|March 1, 2006
Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteersDesiree L Tomilo, Patrick F Smith, Abayomi B Ogundele, et al.
Clinical Ophthalmology (Auckland, N.Z.)|May 2, 2019
A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteersPaul M Karpecki, Sidney L Weiss, William G Kramer, et al.
Pageof 1